MGTX trades 140.3% below Wall Street's consensus target of $21.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MGTX achieves its forward estimates and maintains a stable P/E multiple of 29.1x. This scenario reflects the blended consensus of 7 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of November 17, 2026, MeiraGTx Holdings plc (MGTX) has a Wall Street consensus price target of $21.00, based on estimates from 7 covering analysts. With the stock currently trading at $8.46, this represents a potential upside of +140.3%. The company has a market capitalization of $783M.
Analyst price targets range from a low of $16.00 to a high of $26.00, representing a 48% spread in expectations. The median target of $21.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 7 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, MGTX trades at a trailing P/E of 10.5x and forward P/E of 29.1x. Analysts expect EPS to grow -62.9% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $9.08, with bear and bull scenarios of $5.72 and $11.96 respectively. Model confidence stands at 46/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
OCGNOcugen, Inc. | $257M | $0.76 | $5.00 | +546.8% | Buy | — | 6 |
EDITEditas Medicine, Inc. | $280M | $1.82 | $5.50 | +194.1% | Buy | — | 26 |
CRSPCRISPR Therapeutics AG | $3.9B | $40.15 | $64.14 | +58.9% | Buy | — | 38 |
NTLAIntellia Therapeutics, Inc. | $1.1B | $9.78 | $20.71 | +110.0% | Buy | — | 39 |
BEAMBeam Therapeutics Inc. | $2.1B | $20.65 | $66.00 | +215.2% | Buy | — | 28 |
ARWRArrowhead Pharmaceuticals, Inc. | $6.1B | $42.99 | $101.56 | +129.7% | Buy | — | 22 |
IONSIonis Pharmaceuticals, Inc. | $4.5B | $26.96 | $84.92 | +203.2% | Buy | — | 33 |
ALNYAlnylam Pharmaceuticals, Inc. | $20.9B | $156.50 | $330.54 | +106.9% | Buy | 8.7x | 52 |
REGNRegeneron Pharmaceuticals, Inc. | $98.7B | $957.76 | $904.60 | -5.0% | Buy | 14.0x | 49 |
RAREUltragenyx Pharmaceutical Inc. | $1.6B | $16.70 | $25.54 | +60.6% | Buy | — | 34 |
Quick answers to the most common questions about buying MGTX stock.
The consensus Wall Street price target for MGTX is $21, representing 140.3% upside from the current price of $8.46. With 7 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
MGTX has a consensus rating of "Buy" based on 7 Wall Street analysts. The rating breakdown is predominantly bullish, with 7 Buy/Strong Buy ratings. The consensus 12-month price target of $21 implies 140.3% upside from current levels.
MGTX trades at a forward P/E of 29.1333x, representing a moderate valuation. With analysts targeting $21 (140.3% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $26 for MGTX, while the most conservative target is $16. The consensus of $21 represents the median expectation. Our quantitative valuation model projects a bull case target of $12 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
MGTX is moderately covered, with 7 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 7 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MGTX stock forecast based on 7 Wall Street analysts shows a consensus price target of $21, with estimates ranging from $16 (bear case) to $26 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $9, with bear/bull scenarios of $6/$12.
Our quantitative valuation model calculates MGTX's fair value at $9 (base case), with a bear case of $6 and bull case of $12. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 46/100.
MGTX trades at a forward P/E ratio of 29.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 10.5x. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Wall Street analysts are very optimistic on MGTX, with a "Buy" consensus rating and $21 price target (140.3% upside). 7 of 7 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MGTX analyst price targets range from $16 to $26, a 48% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $21 consensus represents the middle ground. Our model's $6-$12 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.